[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651311":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":63,"collaborators":67,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":106,"whyStopped":18,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"University of Macau","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with PPD","EXPERIMENTAL","Participants diagnosed with postpartum depression ((n=40) will receive standardized repetitive transcranial magnetic stimulation (rTMS) treatment targeting the left dorsolateral prefrontal cortex. Multimodal biomarkers will be evaluated as predictors of treatment response.",[13],"Device: Repetitive Transcranial Magnetic Stimulation (rTMS)",{"label":15,"type":16,"description":17,"interventionNames":18},"Woman in late pregnancy","NO_INTERVENTION","Pregnant women in the third trimester of pregnancy (n=200) will be recruited from the obstetrics outpatient clinics and inpatient wards of Mirror Lake Hospital. Participants will undergo comprehensive multimodal assessments during late pregnancy, including psychological questionnaires, electroencephalography (EEG), autonomic measures, inflammatory markers, and hormonal measures. Follow-up assessments will be conducted at 2 weeks, 1 month, and 3 months postpartum to investigate longitudinal changes associated with postpartum depression risk and progression.",null,{"label":20,"type":16,"description":21,"interventionNames":18},"Healthy Non-Parturient Control (HC)","Healthy non-pregnant and non-postpartum women (n=50) recruited from the University of Macau and the local community. This group consists of age-matched individuals with no history of psychiatric disorders, serving as a baseline control.",[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":18},"DEVICE","Repetitive Transcranial Magnetic Stimulation (rTMS)","Participants diagnosed with postpartum depression will receive a standardized repetitive transcranial magnetic stimulation (rTMS) intervention targeting the left dorsolateral prefrontal cortex (DLPFC). Treatment will be administered by trained clinicians using a neuronavigation-assisted rTMS system. Resting motor threshold (RMT) will be determined prior to treatment, and coil positioning will be guided by a robotic navigation system with a localization error of less than 1 mm.\n\nStimulation will be delivered at 10 Hz and 120% of the individual resting motor threshold. Each train will last 4 seconds with an inter-train interval of 26 seconds, for a total of 3,000 pulses per session. Participants will receive 20 treatment sessions over 4 weeks (5 sessions per week).",[9],[29],{"name":30,"affiliation":31,"role":32},"Cheng Teng Ip, PhD","Institute of Collaborative Innovation, University of Macau","STUDY_CHAIR",[34],{"name":30,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","(853) 8822-9378","(853) 8822-245","chengtengip@um.edu.mo",[40,51],{"facility":41,"status":18,"city":42,"state":18,"zip":43,"country":44,"countryCode":18,"cosmosGeoPoint":45,"geoPoint":50,"contacts":18},"Kiang Wu Hospital","Macao","999078","Macau",{"type":46,"coordinates":47},"Point",[48,49],113.54611,22.20056,{"lat":49,"lon":48},{"facility":52,"status":18,"city":42,"state":18,"zip":43,"country":44,"countryCode":18,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"the Center for Cognitive and Brain Sciences, Research Building N21",{"type":46,"coordinates":54},[48,49],{"lat":49,"lon":48},[57,59],{"name":58,"role":35,"phone":36,"phoneExt":18,"email":38},"Cheng-Teng Ip, Ph.D",{"name":60,"role":35,"phone":61,"phoneExt":18,"email":62},"Juha Silvanto, Ph.D","(853) 8822-4930","juhasilvanto@um.edu.mo",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Cheng Teng IP","Assistant Professor",[68],{"name":41,"class":6},"100651311","multimodal-biomarkers-and-precision-tms-for-postpartum-depression-100651311",false,"NCT07757815","Multimodal Biomarkers and Precision TMS for Postpartum Depression","Multimodal Biomarkers and Robot-Guided Precision TMS for Early Detection and Treatment of Postpartum Depression","MOTHER-TMS","Inclusion Criteria:\n\n* Biological female, aged 18-45 years.\n* For HR-PPD and LR-PPD groups: Pregnant women in the third trimester (≥ 32 weeks gestation) with a singleton pregnancy.\n* For HR-PPD group: Beck Depression Inventory (BDI) score ≥ 14 during the third trimester.\n* For LR-PPD group: BDI score \\\u003C 14 during the third trimester, with no history of depression.\n* For HC group: Healthy women with no pregnancy in the past 12 months.\n* No history of central nervous system diseases or major medical\u002Fsurgical conditions.\n* No history of medication use that may interfere with EEG or ECG measurements.\n* Willing and able to complete baseline and follow-up assessments and provide written informed consent.\n\nExclusion Criteria:\n\n* Multiple pregnancies, preterm labor, or severe pregnancy complications (e.g., pre-eclampsia, gestational diabetes with complications).\n* Life-threatening emergencies during delivery (e.g., amniotic fluid embolism, major hemorrhage).\n* Cognitive impairment or language barriers that hinder cooperation with assessments.\n* History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n* Other conditions that, in the opinion of the investigator, make the participant unsuitable for the study.",true,"FEMALE","18 Years","45 Years",{"count":82,"type":83},290,"ESTIMATED","INTERVENTIONAL",[86],"NA","The purpose of this study is to identify multimodal biological markers associated with postpartum depression (PPD) and to evaluate the effectiveness of precision brain stimulation treatment. PPD is a common mental health condition after childbirth that can affect maternal well-being and early child development. Current identification of PPD relies largely on clinical assessments and screening questionnaires, which may not fully capture underlying biological changes. This study uses brain activity, cardiac signals, blood-based biomarkers, interoceptive assessments, and clinical measures to characterize multimodal biological profiles associated with PPD and treatment response.\n\nThe main questions it aims to answer are:\n\n* What multimodal biological differences exist between women with diagnosed PPD and healthy comparison groups, including postpartum and non-postpartum controls?\n* Which biological or psychological markers can predict whether a patient will respond well to repetitive transcranial magnetic stimulation (rTMS) treatment?\n* Can a clinical model be created to help doctors choose the best treatment based on these markers? The study focuses on characterizing multimodal biological differences in women with diagnosed PPD and examining clinical response profiles following rTMS treatment, rather than predicting the onset of PPD in the general population.\n\nParticipants will:\n\n* Undergo electroencephalography (EEG) using a 128-channel cap to measure neural activity.\n* Have electrocardiography (ECG) recorded to analyze heart rate variability and autonomic function.\n* Provide blood samples to measure inflammatory cytokines, endocrine levels, and metabolic markers.\n* Complete Interoceptive Assessments (tasks to measure awareness of internal body signals) and clinical psychological surveys.\n* Complete follow-up assessments via online surveys and scheduled visits at 2 weeks, 1 month, and 3 months postpartum.\n\nParticipants in the PPD group will:\n\n* Receive 4 weeks of high-precision, robot-guided rTMS treatment (20 sessions total).\n* Undergo pre-intervention multimodal assessments, including EEG, ECG, blood biomarkers, and interoceptive tasks, to identify potential predictors of clinical response to rTMS treatment.",[89],"Depression, Postpartum",[91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Repetitive Transcranial Magnetic Stimulation","Electroencephalography","Postpartum Depression","Biomarkers","Electrocardiography","Interoception","Machine Learning","Blood biomarkers","Hormonal Measures","Interleukin-6 (IL-6)","Multidimensional Assessment of Interoceptive Awareness-2 (MAIA-2)","Body Perception Questionnaire-Short Form (BPQ-SF)","WHO Quality of Life Instrument-Short Form (WHOQOL-BREF)","Hamilton Depression Rating Scale (HAMD-17)","Beck Depression Inventory-II (BDI-II)","NOT_YET_RECRUITING","2026-08-05",{"date":109,"type":110},"2026-08-11","ACTUAL",{"date":112,"type":83},"2026-09-01",{"date":114,"type":83},"2031-08-31",{"name":5,"class":6},2]